

9th Annual ENETS Conference
for the
**Diagnosis and Treatment of
Neuroendocrine Tumor Disease**

**7-9 March 2012
Copenhagen, Denmark**



PRELIMINARY PROGRAM

Scientific Organizing Committee

Philippe Ruzsniewski, Clichy, France
Kjell Öberg, Uppsala, Sweden
Guido Rindi, Rome, Italy
Bertram Wiedenmann, Berlin, Germany
Martyn Caplin, London, United Kingdom
Dermot O'Toole, Clichy, France
Massimo Falconi, Verona, Italy
Beata Kos-Kudła, Katowice, Poland
Ramon Salazar, Barcelona, Spain

Conference Organization

ENETS Office
c/o Charité Universitätsmedizin
Campus Virchow-Klinikum
Hepatology and Gastroenterology
Augustenburger Platz 1
D-13353 Berlin, Germany
Tel.: +49 30 450-553096 (general information); +49 8142 4484896 (hotels)
Fax: +49 30 450-565996
www.neuroendocrine.net
ENETS-annual-conference@charite.de

Conference Venue

Tivoli Hotel & Congress Center
Arni Magnussons Gade 2-4
DK-1577 Copenhagen V
Tel. +45 4599 0000
www.tivolicongresscenter.com

REGISTRATION and MATERIAL PICK-UP:

Conference registration (conference material pick-up) will take place at the entrance area of the conference venue, in front of the plenary room. Registration begins on Tuesday, 6 March 2012, from 2:00 p.m. until 6:00 p.m. Registration then continues on Wednesday, 7 March, at 7:30 a.m. and runs until 9:00 a.m., which is when the postgraduate course begins. The area will remain open on Thursday and Friday, from 7:30 until 6:00 p.m. In addition, the ENETS Office (first floor, Pantomimen Room) will be open from Wednesday until Friday, from 8:00 a.m. until 6:00 p.m.

ENETS POST-GRADUATE COURSE

Wednesday, 7 March 2012

Prior online registration and payment (€100 per participant) required

8:15 – 9:15 *Registration and coffee*

9:15 – 9:35 Introduction and overview of NET management – *M. Caplin (UK)*

9:35 – 9:55 Histopathology of NETs, the new WHO classification – *J.Y. Scoazec (France)*

9:55 -10:15 Chromogranin A as a marker for NET – *B. Wiedenmann (Germany)*

10:15 - 10:35 MEN-1, MEN-2, Von Hippel Lindau, Tuberosc Sclerosis who and how to screen – *W. de Herder (Netherlands)*

10:35 – 11:05 *Coffee break*

11:05 – 11:25 Biotherapies for NETs – *K. Öberg (Sweden)*

11:25 – 11:45 Chemotherapy for NETs – *T. Meyer (UK)*

11:45 – 12:05 Lutetium or Yttrium PRRT: What's the difference? - *J. Cwikła (Poland)*

12:10 – 12:35 Clinical Case Discussion 1

12:35 – 14:10 **Lunch and PFIZER SYMPOSIUM: Program TBA**

14:10 – 14:30 Transarterial embolisation for NET liver mets: Still a role? *P. Ruzniewski (France)*

14:30 – 14:50 Liver surgery and when to consider transplant? *TBA*

14:50 – 15:10 Unusual secretory NETs – clues and treatment *B. Eriksson (Sweden)*

15:15 – 15:40 Clinical Case Discussion 2

15:40 – 16:00 *Coffee break*

16:00 – 16:20 Refractory carcinoid syndrome – what else can you do? *B. Kos-Kudła (Poland)*

16:20 – 16:40 Carcinoid Heart Disease *D. Knight (UK)*

16:40 – 17:05 Clinical Case Discussion 3

17:05 – 17:15 Concluding remarks

17:30 **IPSEN SYMPOSIUM: Program TBA**

Meet the Professor

Limited entrance; prior online registration required

7:30 – 9:00 a.m.

Management of medullary thyroid cancer

(Rooms 11 & 12, 1st floor)

(sponsored by Pfizer Pharmaceuticals)

A.M. Colao, Naples, Italy

Peritoneal carcinomatosis: surgical and medical management

(Room Dansetten, 1st floor)

(sponsored by Ipsen)

R. Kianmanesh, Colombes, France

Lung NETs

(Room Divanen, 2nd floor)

(sponsored by Ipsen)

E. Lim, London, United Kingdom

PLENARY SESSION

Room: Tivoli Congress Hall, ground floor

9:00 – 9:15 a.m.

Welcome and Introduction

P. Ruzzniewski, Clichy, France; U. Knigge, Copenhagen, Denmark

9:15 – 10:45 a.m.

SESSION 1: IMAGING – HOW MUCH IS REALLY NEEDED AND HOW MUCH CAN WE AFFORD?

Chairs: D. O’Toole, Clichy, France; A. Sundin, Stockholm, Sweden

9:15 – 9:35 a.m.

CT scan including perfusion and MRI including diffusion

V. Vilgrain, Clichy, France

9:35 – 9:55 a.m.

Current challenges for the endoscopist

A. Larghi, Rome, Italy

9:55 – 10:15 a.m.

Nuclear and molecular imaging

L. Bodei, Milan, Italy

10:15 – 10:45 a.m.

The clinician’s view and discussion

U. Pape, Berlin, Germany

10:45 – 11:00 a.m.

2012 ENETS Life Achievement Award:

Recipient: *S. Lamberts, Rotterdam, The Netherlands*

Dedication: *W. de Herder, Rotterdam, The Netherlands*

Chair: *P. Ruzzniewski, Clichy, France*

11:00 – 11:30 a.m.

COFFEE BREAK and POSTER VIEWING

11:30 a.m. – 12:30 p.m. SESSION 2: SELECTED ABSTRACTS - BASIC SCIENCE RELATED TO CANCER BIOLOGY

In Carstensen Room, lower level

Chairs: G. Rindi, Rome, Italy; A. Kjaer, Copenhagen, Denmark

11:30 – 11:45 a.m.

11:45 – 12 noon

12 noon – 12:15 p.m.

12:15 – 12:30 p.m.

12:30 – 1:00 p.m.

HOT NEWS IN NETS

R. Jensen, Bethesda, MD, USA

1:00 – 2:30 p.m.

LUNCH AND POSTER VIEWING

<p>2:30 – 3:30 p.m. SESSION 3A: MANAGEMENT OF GEP GRADE 2 AND 3 NEOPLASMS <i>In Tivoli Congress Hall</i> <i>Chair: E. Raymond, Clichy, France; F. Costa, Sao Paulo, Brazil</i></p> <p>2:30 – 3:00 p.m. G2 NETs: Are they all the same? <i>M. Pavel, Berlin, Germany</i></p> <p>3:00 – 3:30 p.m. G3, High-grade NEC: What are they and how to deal with them? <i>E. Baudin, Villejuif, France</i></p>	<p>2:30 – 3:30 p.m. SESSION 3B: PATHWAYS AND NEW MOLECULAR TARGETS <i>In Carstensen Room, lower level</i> <i>Chairs: R. Salazar, Barcelona, Spain; J. Yao, Houston, TX, USA</i></p> <p>2:30 – 2:50 p.m. RAF Signalling <i>N. Fazio, Milan, Italy</i></p> <p>2:50 – 3:10 p.m. mTOR – AKT3 <i>J. Yao, Houston, TX, USA</i></p> <p>3:10 – 3:30 p.m. Angiogenesis and VEGF inhibition <i>O. Casanova, Barcelona, Spain</i></p>
--	--

3:30 – 4:00 p.m.

COFFEE BREAK and POSTER VIEWING

4:00 – 5:00 p.m.

GENERAL ASSEMBLY (for ENETS members only; in Carstensen Room, lower level)

5:30 – 7:00 p.m.

NOVARTIS SYMPOSIUM: Program TBA

Friday, 9 March 2012

Meet the Professor

Limited entrance; prior online registration required

7:30 – 8:30 a.m.

Use of TKI's management of side effects

*(Rooms 11 & 12, 1st floor)
(sponsored by Pfizer Pharmaceuticals)*

M. Schmidinger, Vienna, Austria

Paraganglioma and malignant pheochromocytoma

(Room Dansetten, 1st floor)

D. Ferone, Genoa, Italy

Management of rare functional tumors (insulinoma, glucagonoma, VIPOMA)

(Room Divanen, 2nd floor)

(sponsored by Pfizer Pharmaceuticals)

D. O'Toole, Clichy, France

8:30 – 10:00 a.m.

SESSION 4A: MEN-1

In Tivoli Congress Hall

*Chairs: S. Marx, Bethesda, MD, USA;
W. de Herder, Rotterdam,
The Netherlands*

8:30 – 8:50 a.m.

MEN-1 gene and genetic diagnosis

S. Marx, Bethesda, MD, USA

8:50 – 9:10 a.m.

**Treatment of hyperparathyroidism:
When and how?**

M.L. Brandi, Florence, Italy

9:10 – 9:30 a.m.

**Duodenal and pancreatic surgery:
The end of a controversy?**

D. Bartsch, Marburg, Germany

9:30 – 9:45 a.m.

Recommendations for patient follow-up

B. Skogseid, Uppsala, Sweden

9:45 – 10:00 a.m.

Q & A

8:30 – 10:00 a.m.

**SESSION 4B: BASIC SCIENCE –
WHAT'S NEW?**

In Carstensen Room, lower level

*Chairs: A. Scarpa, Verona, Italy;
N. Papadopoulos, Baltimore, MD, USA*

8:30 – 8:50 a.m.

**Genomics – new generation sequencing:
What's it good for?**

*N. Papadopoulos, Baltimore, MD,
USA*

8:50 – 9:10 a.m.

SSTR mutants: Any significance?

J. Castano, Cordoba, Spain

9:10 – 9:30 a.m.

Circulating tumor cells: Do they matter?

M. Khan, London, United Kingdom

9:30 – 10:00 a.m.

MIR: Any good for NETs?

A. Scarpa, Verona, Italy

8:30 – 10:00 a.m.

**SESSION 4C:
NET NURSE MEETING**

Location: TBA

8:30 – 8:50 a.m.

Introduction

P. Davies

8:50 – 9:10 a.m.

**NETs: New treatments (IV, oral
and SC)**

L. Lemmens

9:10 – 9:30 a.m.

**NETs: Side-effects of new
treatments**

J. Falkerby

9:30-10:00 am

**New educational support for
nurses working with NET
patients**

C. Bouvier

10:00 – 11:00 a.m.

COFFEE BREAK and POSTER VIEWING

11:00 a.m. – 12 noon **SESSION 5: SELECTED ABSTRACTS - CLINICAL RESEARCH**
In Tivoli Congress Hall
Chairs: E. Mitry, Saint Cloud, France; J. Cwikła, Warsaw, Poland

11:00 – 11:15 a.m.

11:15 – 11:30 a.m.

11:30 – 11:45 a.m.

11:45 – 12 noon

12 noon – 1:00 p.m. **SESSION 6: CASE PRESENTATIONS FROM THE ENETS ADVISORY BOARD**
Chairs: A. Grossman, London, United Kingdom; A. Couvelard, Paris, France

12 noon – 12:20 p.m.

12:20 – 12:40 p.m.

12:40 – 1:00 p.m.

1:00 – 2:00 p.m. **LUNCH and POSTER VIEWING**

2:00 – 2:15 p.m. **2012 Young Investigator Awards**

2:15 – 4:15 p.m. **SESSION 7: INTEGRATED NET MANAGEMENT (INTERACTIVE SESSION)**
Chair: B. Wiedenmann, Berlin, Germany

2:15 – 2:45 p.m. **Pancreas NET/C**
P. Ruszniewski, Clichy, France

2:45 – 3:15 p.m. **GI-NET/C**
K. Öberg, Uppsala, Sweden

3:15 – 4:15 p.m. **Burning Questions B. Wiedenmann, Berlin, Germany**

	PRO	CON
Targeted Therapies (as first line)	<i>E. Baudin, Villejuif, France</i>	<i>R. Jensen, Bethesda, MD, USA</i>
PRRT (as first line)	<i>D. Kwekkeboom, Rotterdam, The Netherlands</i>	<i>TBA</i>
Biomarkers	<i>M. Pavel, Berlin, Germany</i>	<i>J. Yao, Houston, TX, USA</i>

END OF MEETING